Name:
Treat Stroke to Target Trial: Safety and Efficacy
Description:
Treat Stroke to Target Trial: Safety and Efficacy
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/15ea3f6b-964d-4bd9-974f-d978fb3467db/thumbnails/15ea3f6b-964d-4bd9-974f-d978fb3467db.jpeg?sv=2019-02-02&sr=c&sig=J0dhrFO4tye%2BR9QfpDVWesNG%2FhvINosc2WffN582pgU%3D&st=2024-04-29T21%3A43%3A11Z&se=2024-04-30T01%3A48%3A11Z&sp=r
Duration:
T00H03M10S
Embed URL:
https://stream.cadmore.media/player/15ea3f6b-964d-4bd9-974f-d978fb3467db
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/15ea3f6b-964d-4bd9-974f-d978fb3467db/18777423.mp3?sv=2019-02-02&sr=c&sig=ptyeL3g3Q0pzH%2BzuBcPhdFOPvxJvuf6xMaZt6LUNA%2Bg%3D&st=2024-04-29T21%3A43%3A11Z&se=2024-04-29T23%3A48%3A11Z&sp=r
Upload Date:
2022-02-28T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
>> Practice Impact Extra podcasts are derived from Hurst's The Heart Board Review, and other online resources available only through accesscardiology.com. [ Music ] We've all known that atherosclerosis involves the brain through vascular circulation, the coronary arteries, the renal arteries, and the peripheral arteries. The question is in this family, is aggressive treatment going to positively impact on all the individual components of the family of atherosclerosis? [ Music ] Dr. Bernie here, and welcome to Practice Impact Extra.
Treat stroke to target. This was an important trial. This -- I really think a very important trial presented at the American Heart meetings in 2019. The goal of this trial was to assess the safety and efficacy of aggressive lipid-lowering with statins among patients with established atherosclerotic cardiovascular disease, and a recent history of an ischemic stroke or TIA. Previous studies often combined stroke and MI as endpoints and did not isolate stroke assessment.
This trial randomized patients to statin therapy with a target goal of LDL cholesterol of less than 70 or in the other group between 90 and 110. And they used cerebral infarction and stroke and myocardial infarction, unstable angina, and CV death as their primary endpoint. 2,800 patients were enrolled for a duration of 5.3 years. So what do the results of this study demonstrate?
They indicated that aggressive LDL reduction with a goal of less than 70 was superior to the modest reduction of LDL between the ranges of 90 and 110 in patients with atherosclerotic cardiovascular disease and evidence of ischemic stroke or TIA. Where was the benefit really gained? Well, the benefit was really driven by a greater reduction in non-fatal CVA and stroke events. Though the trial was discontinued prematurely for funding issues, I believe these results remain very important.
So what's my take? This is yet another trial that supports that lowers better cholesterol for the family of atherosclerotic disease, including coronary artery disease, peripheral artery disease, and cerebral vascular disease. In particular, this trial provides data that in stroke risk reduction, the lowering of cholesterol aggressively is the right thing to do. Thanks for joining me and see you next time on Practice Impact Extra.
>> We hope you enjoyed this podcast from McGraw-Hill. Subscribers to AccessCardiology have instant access to over 25,000 pages of rich medical content, receive medical updates from trusted experts, and have access to other special features. To subscribe or learn more, please visit accesscardiology.com.